CBR (PO IG)
Subsidies for innovations – we invest in your future
‘Establishment of the Centre for Research and Development of Biotechnology Products in IBSS BIOMED’, co-financed from public funds under sub-measure 4.5.2 Support for investments in the modern services sector and 4.5 Support for investments of high priority for the economy of the priority axis 4 Investments in innovative undertakings of the Innovative Economy Operational Programme, 2007 – 2013.
Name of the beneficiary:
Instytut Biotechnologii Surowic i Szczepionek BIOMED Spółka Akcyjna
Project value:
PLN 9,896,899.80
Participation of the European Union:
PLN 4,023,130.00
Performance Period:
2012 – 2015
Project description
The main objective of this project is to increase the innovation and competitiveness of the Company on the domestic and international market by creating in its structure a completely new organisational unit operating within the company, i.e. the Centre for Research and Development of Biotechnology Products (hereinafter referred to as the CBR), which will perform research and development operations in the field of biotechnology, related to the development of new and improved products, in two main research areas:
- the development of new alternative products for antibiotics,
- the development of new and the improvement of existing products for the prevention and control of bacterial infections, including antibiotics.
As such, research will focus on the development of new antibiotic-resistant products for the elimination of infections, including antibiotic-resistant, using a different mechanism of action than current antibiotics, and the improvement of existing products for the prevention and control of antibiotic-resistant bacterial infections.
In addition, CBR will carry out expert research for the Company’s needs in the field of literature analysis and patent analysis, as well as didactic activities for the needs of university students who annually complete student internships at IBSS BIOMED S.A.
The main objective of the project will be implemented through the achievement of specific objectives including:
- creating 11 new research posts;
- ensuring a high percentage of newly admitted employees with higher education – 100%;
- introducing 2 new innovative products manufactured according to the new technology to the offer:
- a preparation for dry and atopic skin care,
- a preparation intended for use in the inflammation of the throat;
- improved Pseudovac vaccine;
- development of a new product on the Q10 scale for use on wounds and ulcers infected with antibiotic-resistant bacteria;
- development and implementation of a new analytical method – an alternative method to animal testing in the evaluation of the activity of diphtheria-tetanus vaccines;
- introduction and implementation of new technology for the production of biotechnology products;
- development of cleaning technology and concentration of bacterial supernatants;
- establishing cooperation with at least 3 entities from the SME sector;
- implementation of new research projects in the field of biotechnology;
- development and validation of new analytical methods;
- introducing solutions contributing to ensuring equality between women and men and non-discrimination;
- introduction of solutions resulting in a positive impact on environmental protection.
In addition, the implementation of the project will have an impact on the socio-economic environment, i.e. including:
- creating new posts in the high technology industry;
- ensuring accessibility for Polish biotechnology specialists to state-of-the-art research technologies, and thus providing them with development opportunities;
- stimulating the development of Polish science in the area of biotechnology;
- introducing innovative products on the European market in response to a growing social problem, i.e. an increase in dangerous infections caused by antibiotic-resistant bacteria, and thus a significant positive impact on improvement in the field of health care policy;
- providing final recipients, i.e. patients with access to innovative and safe methods of prevention and treatment.
The scope of the investment:
- Modernisation and adaptation of the premises owned by the Company (on the area of
49 m2), in order to create a Technological Laboratory and a modern double-corridor Animal House. - Establishment of research laboratories (extension of the building area: 562.20 m2) including: Immunology, Phage, Chemistry, Cell Culture, and Microbiology Laboratories, Laboratory for the Preparation of Reagents and Samples, Equipment Room, Reagent Storage and small laboratory equipment for auxiliary and social rooms.
- Purchase of fixed assets including: a) research equipment for CBR laboratories; b) equipment of the Animal Farm; and c) furniture fittings for laboratories and social rooms of the CBR.
Recommended sites: